July 1 (Reuters) - Recce Pharmaceuticals Ltd (RCE) :
- RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE I/II URINARY TRACT INFECTION (UTI) / UROSEPSIS RAPID INFUSION TRIAL OF RECCE® 327
- RECCE PHARMACEUTICALS LTD: NO SERIOUS ADVERSE EVENTS AND CLINICALLY SIGNIFICANT CHANGES OBSERVED, REINFORCING SAFETY PROFILE OF R327
- RECCE PHARMACEUTICALS LTD: ON TRACK TO INITIATE PHASE II TRIAL OF R327 IN PATIENTS WITH URINARY TRACT INFECTIONS IN H2 2024
News: RCE Recce Pharmaceuticals Says No Serious Adverse Events And Clinically Significant Changes...
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.010(2.17%) |
Mkt cap ! $104.2M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 47.5¢ | 46.0¢ | $49.67K | 106.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 159816 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.5¢ | 26610 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RCE (ASX) Chart |